m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00493)
Target Name hsa-miR-582-3p
Gene Name hsa-miR-582-3p
miRBase ID
MIMAT0004797
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
hsa-miR-582-3p can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Methyltransferase-like 3 (METTL3) [WRITER]
 Regulator Info 
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary NKILA physically interacted with and suppressed hsa-miR-582-3p, which was regulated by METTL3-mediated N6 -methyladenosine (m6A) modification. YAP1 was a target of NKILA via miR-582-3p and NKILA functioned partially via YAP1 in CCA.
Responsed Disease Intrahepatic cholangiocarcinoma ICD-11: 2C12.10
 Disease Info 
In-vitro Model TFK-1 Cholangiocarcinoma Homo sapiens CVCL_2214
RBE Intrahepatic cholangiocarcinoma Homo sapiens CVCL_4896
HuH-28 Cholangiocarcinoma Homo sapiens CVCL_2955
HuCC-T1 Intrahepatic cholangiocarcinoma Homo sapiens CVCL_0324
HIBEpic (Human intrahepatic bile duct epithelial cells)
CC-LP-1 Intrahepatic cholangiocarcinoma Homo sapiens CVCL_0205
In-vivo Model To detect the effect of NKILA on CAA growth, 5 × 106 control and NKILA-depleted HuCCT1 cells (n = 4 per group) were subcutaneously injected into male BALB/c nude mice (4-6 weeks old).
Liver cancer [ICD-11: 2C12]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary NKILA physically interacted with and suppressed hsa-miR-582-3p, which was regulated by METTL3-mediated N6 -methyladenosine (m6A) modification. YAP1 was a target of NKILA via miR-582-3p and NKILA functioned partially via YAP1 in CCA.
Responsed Disease Intrahepatic cholangiocarcinoma [ICD-11: 2C12.10]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
In-vitro Model TFK-1 Cholangiocarcinoma Homo sapiens CVCL_2214
RBE Intrahepatic cholangiocarcinoma Homo sapiens CVCL_4896
HuH-28 Cholangiocarcinoma Homo sapiens CVCL_2955
HuCC-T1 Intrahepatic cholangiocarcinoma Homo sapiens CVCL_0324
HIBEpic (Human intrahepatic bile duct epithelial cells)
CC-LP-1 Intrahepatic cholangiocarcinoma Homo sapiens CVCL_0205
In-vivo Model To detect the effect of NKILA on CAA growth, 5 × 106 control and NKILA-depleted HuCCT1 cells (n = 4 per group) were subcutaneously injected into male BALB/c nude mice (4-6 weeks old).
References
Ref 1 m(5) C and m(6) A modification of long noncoding NKILA accelerates cholangiocarcinoma progression via the miR-582-3p-YAP1 axis. Liver Int. 2022 May;42(5):1144-1157. doi: 10.1111/liv.15240. Epub 2022 Mar 21.